Patents by Inventor Yasuki Niwa
Yasuki Niwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11890288Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.Type: GrantFiled: July 20, 2023Date of Patent: February 6, 2024Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kiyomi Ohba, Yasuki Niwa, Tetsuji Matsudaira, Maiko Hamada, Ryuta Yamazaki, Tatsuya Ibuki
-
Publication number: 20230364105Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.Type: ApplicationFiled: July 20, 2023Publication date: November 16, 2023Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
-
Publication number: 20230348363Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.Type: ApplicationFiled: February 22, 2023Publication date: November 2, 2023Inventors: Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM, Giulia Bergonzini, Henrik Graden, Lars Johan Andreas Ulander
-
Publication number: 20230312542Abstract: The present invention provides a target protein degradation-inducing compound that is a bifunctional compound having a portion that binds to VHL, which is a substrate recognition protein of a ubiquitin ligase complex, at one end, and a portion that binds to a target protein at the other end. Specifically, a compound represented by the following structural formula (I): wherein each symbol is as defined in the present specification, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: March 30, 2021Publication date: October 5, 2023Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Shuhei YAMAKOSHI, Kouhei ISHIZAWA, Shuichi HAGIHARA, Komei SAKATA, Yasuki NIWA, Minoru TANAKA
-
Patent number: 11667602Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.Type: GrantFiled: December 7, 2021Date of Patent: June 6, 2023Assignees: AstraZeneca AB, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kenneth Lars Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, Yasuki Niwa, Masakazu Fujio, Hans Fredrik Bergström, Stig Jonas Boström
-
Publication number: 20230146717Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.Type: ApplicationFiled: February 5, 2021Publication date: May 11, 2023Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
-
Publication number: 20230078576Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.Type: ApplicationFiled: December 7, 2021Publication date: March 16, 2023Inventors: Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM
-
Patent number: 11542273Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor. A compound represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.Type: GrantFiled: July 4, 2019Date of Patent: January 3, 2023Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Ryuta Yamazaki, Tatsuya Ibuki, Yuichi Sawaguchi, Kiyomi Ohba, Maiko Hamada, Yasuki Niwa, Yuko Ishida, Hideto Maruyama, Shiki Matsuki, Minoru Tanaka
-
Publication number: 20210284654Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor.Type: ApplicationFiled: July 4, 2019Publication date: September 16, 2021Applicants: MITSUBISHI TANABE PHARMA CORPORATION, KABUSHIKI KAISHA YAKULT HONSHAInventors: Ryuta YAMAZAKI, Tatsuya IBUKI, Yuichi SAWAGUCHI, Kiyomi OHBA, Maiko HAMADA, Yasuki NIWA, Yuko ISHIDA, Hideto MARUYAMA, Shiki MATSUKI, Minoru TANAKA
-
Patent number: 9540360Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.Type: GrantFiled: February 12, 2015Date of Patent: January 10, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuyuki Tsuzuki, Daisuke Sawamoto, Toshiaki Sakamoto, Taku Kato, Yasuki Niwa, Nobumasa Awai
-
Publication number: 20150218143Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.Type: ApplicationFiled: February 12, 2015Publication date: August 6, 2015Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuyuki TSUZUKI, Daisuke SAWAMOTO, Toshiaki SAKAMOTO, Taku KATO, Yasuki NIWA, Nobumasa AWAI
-
Patent number: 8987445Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.Type: GrantFiled: March 15, 2012Date of Patent: March 24, 2015Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Yasuyuki Tsuzuki, Daisuke Sawamoto, Toshiaki Sakamoto, Taku Kato, Yasuki Niwa, Nobumasa Awai